MYSTERIOUS: 3 - You Need To See This

Peering Into Bristol-Myers Squibb's Recent Short Interest

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.23% since its last report. The company recently reported that it has 47.34 million shares sold short, which is 2.23% of all regular shares that are available for trading.

Benzinga · May 6, 2022

Check Out What Whales Are Doing With BMY

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · May 5, 2022

Bristol-Myers Squibb's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a 2.81% change since Q4.

Benzinga · May 2, 2022

Check Out What Whales Are Doing With BMY

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 24 strange trades.

Benzinga · Apr 22, 2022

Bristol-Myers Squibb Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Apr 14, 2022

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Apr 8, 2022

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

Benzinga · Apr 1, 2022

Bristol-Myers Squibb Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Mar 28, 2022

Check Out What Whales Are Doing With BMY

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Mar 25, 2022

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Mar 25, 2022